Access Pharma Inks Manufacturing, Development Deal With Jiangsu Aosaikang For ProLindac
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Jiangsu Aosaikang Pharmaceutical inked an agreement with Dallas-based Access Pharm to manufacture, develop and commercialize Access's proprietary product ProLindac for the Greater China Region of Mainland China, Hong Kong, Macao and Taiwan, Access announced June 4
You may also be interested in...
Rhei To Market ADHD Nutraceutical Attental In China
SHANGHAI - Rhei Pharmaceuticals and MethaPharma have inked a deal under which Rhei gains exclusive rights to market and distribute MethaPharma's proprietary nutraceutical product Attental for treating attention-deficit hyperactivity disorder throughout Asia, the two companies announced Feb. 19
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).